<DOC>
	<DOCNO>NCT02278744</DOCNO>
	<brief_summary>This phase I clinical trial investigating use single fraction re-irradiation follow local progression spine cauda equina ( L2 sacrum ) lesions previously receive radiation therapy . Patients treat single-fraction radiation therapy 3 dose level use image-guided stereotactic radiosurgery technique .</brief_summary>
	<brief_title>Trial Salvage Re-Irradiation Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery</brief_title>
	<detailed_description />
	<criteria>Patients must histologic cytologic proof nonhematologic malignancy confirm MSKCC pathologic review Patients must radiographic evidence malignancy spine cauda equina region ( L2 sacrum ) suitable radiation therapy Patients must receive prior external beam radiation therapy region propose SRS reirradiation least 6 month prior plan reirradiation For patient previously treat outside institution , adequate record must available determine true dose cord/cauda receive prior RT . Sufficiency treatment record assess signedoff Medical Physics investigator . Patients must demonstrate progression disease MRI CT assessment spinal cord/cauda within previous radiation field progression may consist increase maximal dimension tumor ≥20 % , compromise spinal cord/cauda equina and/or exit spinal nerve ( assess clinically radiographically ) , . Target lesion size reirradiation must ≤ 2 vertebral body KPS ≥ 60 % Age ≥ 18 year old Patients life expectancy &lt; 6 month predict Adult Comorbidity Index ( ACE27 , see Appendix 1 ) . Patients intradural intramedullary lesion , lesion &lt; 2mm distance tumor spinal cord Patients circumferential epidural disease Systemic chemotherapy deliver plan deliver within ( +/ ) 5 day SRS reirradiation Patients receive bevacizumab within 12 week prior protocol treatment . Unable undergo either myelogram MRI spinal cord/cauda equina and/or exit spinal nerve Patients may receive therapeutically effective dos via external beam approach lesion interest specify Dose Limit Guidelines Evaluation dose previously deliver spinal cord/cauda equina critical structure ( bowel , esophagus , kidney , rectum ) take consideration If repeat irradiation would exceed normal tissue constraint note Appendix 2 , patient ineligible If total prior radiation dose spinal cord/cauda equina and/or sacrum prior treatment exceed 100 Gy BED ( biologically effective dose ) , patient ineligible , total 100 Gy BED determine calculation : BED = nd ( 1 + d/α/β ) , n = number fraction = dose per fraction ; α/β constant spinal cord/cauda/sacrum late effect equal 2 [ Rades 2005 , Nieder 2005 , Sahgal 2012 ] Patients paraspinal extension disease visceral involvement exclusive patient cauda equina sacral disease extension . Abnormal complete blood count . Any following : Platelet count &lt; 75 , K/mcL Hemoglobin level &lt; 9g/dl WBC &lt; 3.5K/mcL Abnormal coagulation profile : INR &gt; 2.5 and/or PTT &gt; 80 Patients anticoagulation medication may safely hold procedure ( ≥ 5 day antiplatelet agent warfarin ; ≥ 24 hour lowmolecular weight heparin formulation ) exclude Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Single-Fraction Stereotactic Radiosurgery</keyword>
	<keyword>Salvage Re-Irradiation</keyword>
	<keyword>14-054</keyword>
</DOC>